Tag: CanniMed Therapeutics
CanniMed Therapeutics Acts to Protect Shareholders from Aurora Cannabis’ Opportunistic Offer and Enable Fair Vote on Newstrike Acquisition with Shareholder Rights Plan SASKATOON, Saskatchewan — (Business Wire) — CanniMed...
Aurora Cannabis Launches Takeover Bid for CanniMed, Invites CanniMed Shareholders to Tender to the Bid Offer currently valued at $24.00 per CanniMed share 56.9% premium to CanniMed closing price...
Aurora Cannabis Announces Intention to Launch Takeover Bid for CanniMed Therapeutics Inc. Provides Comments on CanniMed’s Poison Pill Tactic Aurora’s proposed offer currently valued at $24.00 per CanniMed share...
CanniMed to Acquire Up Cannabis Inc. (Newstrike Resources Ltd. – TSX-V:HIP) to Create a Premier Global Cannabis Company November 17, 2017 SASKATOON, Saskatchewan & OAKVILLE, Ontario–(BUSINESS WIRE)–CanniMed Therapeutics Inc....
CanniMed Acknowledges Aurora Press Release and Announces Exclusivity Agreement and Intention to Acquire Newstrike Resources Ltd. Shareholders advised to take no action at this time. Details regarding acquisition transaction...
Aurora Cannabis Submits Proposal to CanniMed Therapeutics Board Aurora Cannabis Executes Lock-up Agreements with 38% of CanniMed Shareholders VANCOUVER, Nov. 14, 2017 /CNW/ – At the request of IIROC,...
Despite a flood of supply this month, Canadian LP stock performance stands out so far in October as investors have retreated somewhat from the overall sector. The Cannabis Stock...
In September, Health Canada updated market information that showed how oils are growing rapidly. During the quarter ending 6/30, licensed producers (LPs) shipped 5.896mm grams of dried flower, representing...
Investment Bank Mackie Research has published an extensive industry report, initiating coverage on four Canadian LPs. The 74-page report, “The End of Prohibition – Investing in Canada’s Growing Cannabis...
Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (OTC: HMLSF), the world’s first and still only cannabis ETF, has adjusted its portfolio this month as its benchmark, the North...
CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017 SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its financial results for the three and nine...
In contrast to a period when promotion and fluff have grabbed the attention of novice stock investors interested in the legal cannabis theme since early 2013, we are now seeing companies...
After a big 2nd half of 2016 and some strength in early 2017, Canadian LPs were under heavy pressure from April through June following a glut of supply (new...
As the U.S. cannabis industry has evolved over the past few years, so has the market for publicly-traded cannabis stocks. In 2014, very few publicly-traded companies were reporting substantial...
With Canada set to make history this week by tabling legislation to make the nation the first G-7 country to legalize cannabis for adult use, many investors are focusing...
CanniMed Therapeutics Inc. Reports Financial Results for Q1 2017 March 16, 2017 SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) (OTC: CMMDF) today released its financial...
CanniMed Therapeutics Inc. and PharmaChoice Enter into Canada’s First Exclusive Pharmacy Distribution Agreement for Medical Cannabis March 02, 2017 SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX:CMED) (OTC: CMMDF) (“CanniMed”) and...
After a boom in the stock prices of Canadian licensed producers (LPs) in 2016 that left the average stock up more than 355%, the sector is performing very well...
Trial Underway to Provide Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain...
Statement from Health Canada on the Testing of Cannabis for Medical Purposes for Unauthorized Pest Control Products OTTAWA, Feb. 7, 2017 /CNW/ – Recently, two licensed producers of cannabis...
CanniMed Therapeutics Inc. Provides Update on Patient Growth Rates, Sales Volume and Product Supply SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX:CMED) (“CMED” or the “Company”), a leading plant biopharmaceutical company...
Last week, James West of the Midas Letter published interviews of four CEOs of publicly-traded Canadian licensed producers, including Vic Neufeld of Aphria (TSXV: APH) (OTC: APHQF), Brent Zettl of...
Early trading in CanniMed Therapeutics (TSX: CMED) was disappointing, as the recent IPO broke its $12 offering price and traded below the $11.28 underwriters price. In the first half-hour...
CanniMed Therapeutics (TSX: CMED) priced its initial public offering at $12, selling 5mm shares through a syndicate led by AltaCorp Capital to raise $60mm. The underwriters, which also included Canaccord...
The list of Canadian licensed producers (LPs) of cannabis expecting to go public just got longer. CanniMed Therapeutics, the parent of CanniMed Ltd. and Prairie Plant Systems, issued a press...
